MCID: HYP082
MIFTS: 47

Hypopharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Hypopharynx Cancer

MalaCards integrated aliases for Hypopharynx Cancer:

Name: Hypopharynx Cancer 12 15 17
Hypopharyngeal Cancer 12 52 54 71
Malignant Neoplasm of Hypopharynx 12 32
Hypopharyngeal Neoplasms 43 71
Hypopharyngeal Carcinoma 17 71
Malignant Neoplasm of Ill-Defined Sites Within the Lip and Oral Cavity 12
Malignant Neoplasm of Other Specified Sites of Hypopharynx 12
Malignant Neoplasm of Other Specified Hypopharyngeal Site 12
Malignant Neoplasm of Posterior Hypopharyngeal Wall 12
Malignant Neoplasm of Posterior Wall of Hypopharynx 12
Malignant Tumor of Posterior Wall of Hypopharynx 12
Malignant Tumour of Hypopharynx 12
Malignant Hypopharyngeal Tumor 12
Malignant Tumor of Hypopharynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8533
ICD9CM 34 148 148.3 148.9
MeSH 43 D007012
NCIt 49 C7190
SNOMED-CT 67 93831006 93968005
ICD10 32 C13 C13.2 C13.9
UMLS 71 C0020627 C0153398 C0496770 more

Summaries for Hypopharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary : Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to oropharynx cancer and parotid gland cancer. An important gene associated with Hypopharynx Cancer is MIR489 (MicroRNA 489), and among its related pathways/superpathways are Apoptosis Pathway and MicroRNAs in cancer. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include hypopharynx, lymph node and lung, and related phenotypes are liver/biliary system and neoplasm

Related Diseases for Hypopharynx Cancer

Diseases related to Hypopharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 oropharynx cancer 30.5 TP53 SERPINB3 MMP8 EGFR CDKN2A
2 parotid gland cancer 30.3 TP53 SERPINB3
3 oral cancer 30.3 TP53 EGFR CDKN2A
4 in situ carcinoma 30.3 TP53 EGFR CDKN2A
5 esophagitis 30.1 TP53 EGFR CDKN2A
6 larynx cancer 29.9 TP53 SERPINB3 NME1 EGFR CDKN2A
7 squamous cell carcinoma 29.7 TP53 SERPINB3 NME1 EGFR CDKN2A
8 laryngeal squamous cell carcinoma 29.7 TP53 NME1 LINC01537 EGFR CDKN2A
9 oral cavity cancer 29.6 TP53 MMP8 EGFR CDKN2A ALDH2
10 squamous cell carcinoma, head and neck 28.7 TP53 NME1 MMP8 MIRLET7E MET ERCC6
11 laryngeal adenoid cystic carcinoma 10.5 SERPINB3 MMP8
12 esophageal cancer 10.5
13 supraglottis neoplasm 10.5 SERPINB3 MMP8
14 malignant ovarian cyst 10.5 MMP8 MET
15 malignant peritoneal mesothelioma 10.4 EGFR CDKN2A
16 doxorubicin induced cardiomyopathy 10.4 MET EGFR
17 postcricoid region cancer 10.4
18 aryepiglottic fold cancer 10.4
19 anal carcinoma in situ 10.4 TP53 SERPINB3
20 vulvar intraepithelial neoplasia 10.4 TP53 CDKN2A
21 ovarian seromucinous carcinoma 10.4 TP53 CDKN2A
22 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
23 spitz nevus 10.4 TP53 CDKN2A
24 methanol poisoning 10.4 ALDH2 ADH1B
25 frontal lobe neoplasm 10.3 TP53 EGFR
26 peritoneal mesothelioma 10.3 MET EGFR CDKN2A
27 papillary squamous carcinoma 10.3 EGFR CDKN2A
28 sinus cancer 10.3
29 soft tissue sarcoma 10.3 TP53 EGFR
30 suppressor of tumorigenicity 3 10.3 TP53 CDKN2A
31 breast malignant phyllodes tumor 10.3 TP53 EGFR
32 differentiated thyroid carcinoma 10.3 TP53 MET EGFR
33 pyriform sinus cancer 10.3
34 esophagus verrucous carcinoma 10.3 TP53 EGFR CDKN2A
35 verrucous carcinoma 10.2 TP53 EGFR CDKN2A
36 rectal disease 10.2 TP53 SERPINB3 CDKN2A
37 keratinizing squamous cell carcinoma 10.2 TP53 EGFR CDKN2A
38 bone squamous cell carcinoma 10.2 TP53 EGFR CDKN2A
39 vulvar disease 10.2 TP53 EGFR CDKN2A
40 peritoneum cancer 10.2 TP53 EGFR CDKN2A
41 supratentorial cancer 10.2 TP53 EGFR CDKN2A
42 gliomatosis cerebri 10.2 TP53 EGFR CDKN2A
43 basaloid squamous cell carcinoma 10.2 TP53 EGFR CDKN2A
44 fibrillary astrocytoma 10.2 TP53 EGFR CDKN2A
45 inverted papilloma 10.2 TP53 EGFR CDKN2A
46 esophagus adenocarcinoma 10.2 TP53 EGFR CDKN2A
47 lung adenoma 10.2 TP53 EGFR CDKN2A
48 breast carcinoma in situ 10.2 TP53 MET EGFR
49 uterine corpus cancer 10.2 TP53 EGFR CDKN2A
50 vulva cancer 10.2 TP53 EGFR CDKN2A

Comorbidity relations with Hypopharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer

Symptoms & Phenotypes for Hypopharynx Cancer

MGI Mouse Phenotypes related to Hypopharynx Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.56 ALDH2 CDKN2A EGFR ERCC6 MET NGFR
2 neoplasm MP:0002006 9.23 ALDH2 CDKN2A EGFR ERCC6 MET MMP8

Drugs & Therapeutics for Hypopharynx Cancer

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4 Liver Extracts Phase 4
5 Neurotransmitter Agents Phase 4
6 Central Nervous System Stimulants Phase 4
7 Nicotinic Agonists Phase 4
8 Cholinergic Agents Phase 4
9 Dopamine Uptake Inhibitors Phase 4
10 Cytochrome P-450 Enzyme Inhibitors Phase 4
11 Dopamine Agents Phase 4
12 Psychotropic Drugs Phase 4
13 Antidepressive Agents Phase 4
14 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
15
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
16
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
17
Hydroxyurea Approved Phase 3 127-07-1 3657
18
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
19
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
22 Pharmaceutical Solutions Phase 3
23 Antimitotic Agents Phase 3
24 Nutrients Phase 3
25 Trace Elements Phase 3
26 Micronutrients Phase 3
27 Vitamins Phase 3
28 Vitamin B Complex Phase 3
29 Vitamin B9 Phase 3
30 Folate Phase 3
31 Hypolipidemic Agents Phase 3
32 Vitamin B3 Phase 3
33 Lipid Regulating Agents Phase 3
34 Nicotinic Acids Phase 3
35 Vasodilator Agents Phase 3
36 Autonomic Agents Phase 2, Phase 3
37 Muscarinic Agonists Phase 2, Phase 3
38
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
39
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
40
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
41
Indinavir Approved Phase 2 150378-17-9 5362440
42
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Trioxsalen Approved Phase 2 3902-71-4 5585
45
Rabeprazole Approved, Investigational Phase 2 117976-89-3 5029
46
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
47
Zinc Approved, Investigational Phase 2 7440-66-6 32051
48
Zinc oxide Approved Phase 2 1314-13-2
49 Raspberry Approved Phase 1, Phase 2
50
nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
4 A Multicentre Randomised Study Of Parotid Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Head And Neck Cancer Unknown status NCT00081029 Phase 3
5 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
6 Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
7 A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Alginos Oral Suspension (Sodium Alginate 50 mg/ml) for the Treatment of Patients With Laryngopharyngeal Reflux (LPR) Completed NCT01450748 Phase 3 Sodium alginate;Placebo
8 A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
9 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
10 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
11 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
12 Phase III Randomized Clinical Trial to Compare Results of Concurrent Chemo-radiation With Surgery and Postoperative Radiotherapy/Chemoradiotherapy in Advanced Laryngeal and Hypopharyngeal Cancers Terminated NCT00128817 Phase 3
13 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
14 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
15 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
16 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
17 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
18 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
19 Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer Unknown status NCT02262221 Phase 2
20 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
21 Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF) Unknown status NCT01073683 Phase 2 Taxotere (Docetaxel), Cisplatin, 5FU
22 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
23 Randomized Phase II Trial: Swallowing Speech Pathology Intervention During Radiochemotherapy on Patients With Head and Neck Cancer Completed NCT02075385 Phase 2
24 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
25 A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx Completed NCT02055989 Phase 1, Phase 2
26 Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
27 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
28 Post-nasal Drainage as an Extraesophageal Manifestation of Reflux Completed NCT00199953 Phase 2 Rabeprazole 20 mg twice a day for 90-day period treatment
29 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
30 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
31 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
32 Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness Completed NCT00243113 Phase 2 docetaxel
33 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
34 A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab Completed NCT01435252 Phase 2 Cetuximab
35 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
36 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
37 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
38 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
39 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
40 New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT03558035 Phase 2 Induction CT+ CRT group
41 Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer Recruiting NCT03894891 Phase 2 Nivolumab;Cisplatin;Docetaxel
42 INRT- AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy Using Artificial Intelligence-Based Radiomics for Head and Neck Squamous Cell Carcinoma Recruiting NCT03953976 Phase 2
43 Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) Recruiting NCT02757222 Phase 1, Phase 2
44 A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma Not yet recruiting NCT04156698 Phase 2 Docetaxel;Cisplatin;Capecitabine;Camrelizumab;Apatinib
45 Induction Chemotherapy With TPF Followed by Radioimmunotherapy With Cetuximab and Intensity Modulated Radiotherapy (IMRT) Plus Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx: TPF-C-HIT Terminated NCT01245985 Phase 2
46 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
47 Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer. Terminated NCT02924675 Phase 2 Pregabalin;Placebo
48 A Phase I Study of Concomitant Chemoradiotherapy With Gemcitabine, Paclitaxel, and 5-FU for Patients With Advanced and/or Recurrent Cancer of the Head and Neck Unknown status NCT00004097 Phase 1 fluorouracil;gemcitabine hydrochloride;paclitaxel
49 Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors Completed NCT00978081 Phase 1 aminolevulinic acid hydrochloride
50 A Pharmacokinetic Study Evaluating the Safety, Tolerability and Maximally Tolerated Dose of 7-Day Continuous Infusions of L-778,123 in Patients With Recurrent of Refractory Solid Malignancies Completed NCT00003430 Phase 1 L-778,123

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Genetic Tests for Hypopharynx Cancer

Anatomical Context for Hypopharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Hypopharynx Cancer:

19
Hypopharynx

MalaCards organs/tissues related to Hypopharynx Cancer:

40
Lymph Node, Lung, Thyroid, Breast, Skin, Testes, Liver

Publications for Hypopharynx Cancer

Articles related to Hypopharynx Cancer:

(show top 50) (show all 1120)
# Title Authors PMID Year
1
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). 46
20700123 2010
2
[Expression of CD44 and nm23-H1 protein in the primary and metastatic lymph node lesions in supraglottic and hypopharyngeal cancer]. 54 61
16848180 2006
3
Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. 54 61
16308260 2006
4
Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. 54 61
9555115 1998
5
Blocking long noncoding RNA MALAT1 restrained the development of laryngeal and hypopharyngeal carcinoma. 61
31792655 2020
6
Detection of hypopharyngeal cancer (Tis, T1 and T2) by ENT physicians vs gastrointestinal endoscopists. 61
31153665 2020
7
Prognostic value of the radiomics-based model in progression-free survival of hypopharyngeal cancer treated with chemoradiation. 61
31673835 2020
8
PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells. 61
31957270 2020
9
Study on the diagnosis and nursing value of diffusion weighted MR imaging based on neuroendocrine analysis in radiotherapy of laryngeal cancer. 61
31931239 2020
10
Surgical rescue for persistent head and neck cancer after first-line treatment. 61
31982945 2020
11
Analysis of patients who decline treatment for squamous cell carcinoma of the head and neck: National perspective. 61
31895475 2020
12
Expression of the long noncoding RNA RP11-169D4.1-001 in Hypopharyngeal Squamous cell carcinoma tissue and its clinical significance. 61
31512299 2020
13
Morphological analysis of ischemia-reperfusion injury in a cold ischemia model of jejunal free flap for hypopharyngeal reconstruction. 61
31494055 2020
14
Prostanoid receptor genes confer poor prognosis in head and neck squamous cell carcinoma via epigenetic inactivation. 61
31969157 2020
15
A nationwide population-based study to access the risk of metachronous esophageal cancers in head and neck cancer survivors. 61
31964952 2020
16
Endoscopic submucosal dissection for superficial hypopharyngeal cancer with thin endoscope. 61
31691372 2020
17
Homologous recombination enhances radioresistance in hypopharyngeal cancer cell line by targeting DNA damage response. 61
31756687 2020
18
Welding and the risk of head and neck cancer: the ICARE study. 61
31959638 2020
19
Clinical value of ultrasonic imaging in diagnosis of hypopharyngeal cancer with cervical lymph node metastasis. 61
31788065 2019
20
Large neck metastasis of hypopharyngeal cancer. 61
31893118 2019
21
Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma. 61
31845736 2019
22
Tumor cell viability in salvage neck dissections: Poor prognosis predicted by high postradiation nodal SUVmax , p16-negativity, and low nodal shrinkage. 61
31854495 2019
23
Thiamine deficiency in the bereaved after cancer-related spousal loss. 61
31104649 2019
24
[Laryngectomy-still state of the art?] 61
31720696 2019
25
A prospective clinical trial of the second-look procedure for transoral surgery in patients with T1 and T2 laryngeal, oropharyngeal, and hypopharyngeal cancer. 61
31595716 2019
26
Comparative effectiveness of simultaneous integrated boost vs sequential intensity-modulated radiotherapy for oropharyngeal or hypopharyngeal cancer patients: A population-based propensity score-matched analysis. 61
31861029 2019
27
Treatment sequence and survival in locoregionally advanced hypopharyngeal cancer: A surveillance, epidemiology, and end results-based study. 61
31821572 2019
28
The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma. 61
31882379 2019
29
[62-year-old male with condition following emergency tracheotomy in metastasized hypopharyngeal cancer : Preparation for the medical specialist examination: part 39]. 61
31624883 2019
30
Factors associated with suicidal ideation risk in head and neck cancer: A longitudinal study. 61
30690748 2019
31
Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer. 61
31711185 2019
32
Incidence and survival of hypopharyngeal cancer: a Danish Nation-Wide Study from 1980 to 2014. 61
31505992 2019
33
Curved Laryngopharyngoscope With Flexible Next-Generation Robotic Surgical System for Transoral Hypopharyngeal Surgery: A Preclinical Evaluation. 61
31220916 2019
34
Human papillomavirus-associated squamous cell carcinoma of the larynx or hypopharynx: Clinical outcomes and implications for laryngeal preservation. 61
31536842 2019
35
Optimizing Survival Predictions of Hypopharynx Cancer: Development of a Clinical Prediction Model. 61
31693181 2019
36
A Survival Analysis of Hypopharyngeal Cancer Patients: A Hospital-Cancer registry Based Study. 61
31742067 2019
37
Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer. 61
31251350 2019
38
Treatment results of 99 patients undergoing open partial hypopharyngectomy with larynx preservation. 61
31242294 2019
39
Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells. 61
31325530 2019
40
Metastatic lymph node burden predictive of survival in patients undergoing primary surgery for laryngeal and hypopharyngeal cancer. 61
31352569 2019
41
Evaluation of Dynamic CT Scans and Analyzing Its Efficacy Accuracy in Staging of Laryngeal CA: A Prospective Analysis of 30 Patients and Review of Literature. 61
31741971 2019
42
Evaluation of the information given to patients undergoing total pharyngolaryngectomy and quality of life: a prospective multicentric study. 61
31240456 2019
43
[Successful Multidisciplinary Treatment Accomplished by Collaboration of Multiple Clinical Departments for Synchronous Quadruple Cancer]. 61
31506404 2019
44
Transoral robotic surgery in patients with stage III/IV hypopharyngeal squamous cell carcinoma: treatment outcome and prognostic factor. 61
31268399 2019
45
Comparison of Functional Organ Preservation by Concomitant Boost Radiotherapy Versus Concurrent Chemoradiation in Locally Advanced Carcinoma of Larynx or Hypopharynx: A Prospective Randomized Study. 61
31559204 2019
46
Transoral videolaryngoscopic surgery for laryngeal and hypopharyngeal cancer - Technical updates and long-term results. 61
31564510 2019
47
Is Increased Time From Diagnosis to Treatment in Advanced Hypopharynx Cancer Associated With Poorer Outcomes: A Single-Centre Analysis. 61
31569981 2019
48
Laryngo-esophageal dysfunction free survival and propensity score matched analysis comparing organ preservation and total laryngectomy in hypopharynx cancer. 61
31345382 2019
49
Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy. 61
31152682 2019
50
The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients. 61
31470817 2019

Variations for Hypopharynx Cancer

Expression for Hypopharynx Cancer

Search GEO for disease gene expression data for Hypopharynx Cancer.

Pathways for Hypopharynx Cancer

GO Terms for Hypopharynx Cancer

Biological processes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 9.32 TP53 CDKN2A
2 ethanol oxidation GO:0006069 9.26 ALDH2 ADH1B
3 response to UV-B GO:0010224 9.16 TP53 ERCC6
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.96 TP53 EGFR
5 cellular response to drug GO:0035690 8.8 TP53 NME1 EGFR

Molecular functions related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 TP53 MET EGFR

Sources for Hypopharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....